Bio-Thera’s Biosimilar BAT1806 Passes NMPA Review, Targets Roche’s Actemra
China-based Bio-Thera Solutions Ltd (SHA: 688177) has announced that its biosimilar drug BAT1806, modeled after...
Drug
Abbisko’s ABSK021 Gains NMPA Approval for Phase II Study in cGVHD
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced receiving approval from the National...
CStone’s RET Inhibitor Gavreto Approved in Taiwan for Lung and Thyroid Cancers
CStone Pharmaceuticals (HKG: 2616) has announced receiving marketing approval in Taiwan for its RET inhibitor...
Simcere’s COVID-19 Drug SIM0417 Accepted for Special Review by NMPA
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced that the National Medical Products Administration (NMPA)...
Bristol-Myers Squibb’s Opdivo Secures Two New Approvals for Esophageal Cancer in China
US-based pharmaceutical giant Bristol-Myers Squibb (BMS, NYSE: BMY) has received two new indication approvals in...
Henlius’ PD-1 Inhibitor HanSiZhuang Approved for First-Line SCLC Indication
Shanghai Henlius Pharmaceutical Co., Ltd (HKG: 2696) has announced receiving another indication approval from China’s...
3D Medicines’ 3D185 Receives Orphan Drug Designation for Gastric Cancer
China-based oncology specialist 3D Medicines (HKG: 1244) has announced receiving orphan drug designation (ODD) status...
Ascletis Pharma Initiates Dosing in Phase I Trial for COVID-19 Treatment ASC11
China-based Ascletis Pharma Inc. (HKG: 1672) has announced the dosing of four healthy subjects in...
Luye Pharma’s Rykindo Receives FDA Approval for Schizophrenia and Bipolar I Disorder
China-based Luye Pharma Group (HKG: 2186) has announced receiving market approval from the US Food...
Hengrui’s Generic Cyclophosphamide Capsules Approved by China’s NMPA
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving marketing approval from the National Medical...
Akeso’s Penpulimab Secures New Approval for Lung Cancer Indication
China-based Akeso Biopharma (HKG: 9926) has announced receiving another indication approval from the National Medical...
Clover Biopharmaceuticals Plans COVID-19 Vaccine SCB-2019 Launch in China for 2023
China-based Clover Biopharmaceuticals, Ltd (HKG: 2197) has provided updates on its plans for the commercialization...
Amoytop’s AK0706 Receives Clinical Trial Approval for Hepatitis B Treatment
Xiamen-based Amoytop Biotech Co. Ltd has announced receiving clinical trial approval from China’s National Medical...
Sino Biopharma’s PD-L1 Combo with Anlotinib Accepted for Review by China’s CDE
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its New Drug Application (NDA) filing...
Guangzhou’s Overseas Pharma Wins China Clinical Trial Approval for OPL-038
Guangzhou-based Overseas Pharmaceuticals, Ltd has secured clinical trial approval in China for its sustained and...
Xinhua Pharma’s OAB-14 Receives NMPA Approval for Phase I Alzheimer’s Study
China-based Shandong Xinhua Pharmaceutical Co., Ltd (SHE: 000756) has announced receiving approval from the National...
Konruns’ KC1036 Advances to Phase II Study for Lung Adenocarcinoma
Beijing-based Konruns Pharmaceutical Co., Ltd (SHA: 603590) has announced receiving approval from the National Medical...
Harbour BioMed’s HBM1020 Receives FDA Approval for US Phase I Study
Harbour BioMed (HKG: 2142), a global biotech company operating in the Netherlands, the United States,...
Sanofi’s iGlarLixi Approved in China for Type 2 Diabetes Management
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced that the National Medical Products Administration (NMPA)...
Roche’s Polivy Approved by China’s NMPA for Lymphoma Treatment
Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced that the National Medical Products...